Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis
A live, multi-source view of Rigel Pharmaceuticals, Inc. (RIGL): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome.
Sector: Healthcare · Industry: Biotechnology · United States · 172 employees · rigel.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Rigel Pharmaceuticals, Inc. (RIGL) had a market capitalization of $909.1M, a trailing P/E of 2.9 (forward 9.9) and a beta of 1.20; the shares traded in a 52-week range of $24.95 – $52.24 (19.1% over the year).
- Market cap
- $909.1M
- Enterprise value
- $853.8M
- Trailing P/E
- 2.9
- Forward P/E
- 9.9
- Price / book
- 2.13
- EPS (trailing)
- $16.98
- EPS (forward)
- $4.94
- Payout ratio
- 0.0%
- 52-week range
- $24.95 – $52.24
- 52-week change
- 19.1%
- Beta
- 1.20
- Average volume
- 342,526
- Shares outstanding
- 18.7M
- Short % of float
- 17.61%
- Profit margin
- 116.3%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Rigel Pharmaceuticals, Inc. (RIGL) last closed at $47.28 (the last completed close before that scan).
Technicals at the scan: RSI 60 (neutral territory), price +2.6% versus its 20-day average, 20-day versus 50-day average spread +8.8%, MACD histogram -0.15.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 65/100.
Next scheduled company event: in 53 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for RIGL in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
RIGL has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Rigel Pharmaceuticals, Inc. (RIGL) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RIGL.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.